Tesamorelin (10 mg Vial)

Tesamorelin Research Chart

Tesamorelin is researched at 1 mg–2 mg daily by subcutaneous research methodology in educational protocols, typically at night. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Tesamorelin is a synthetic peptide that has been studied in scientific research for its biological properties and mechanisms of action under controlled laboratory conditions. Ongoing research explores its role in metabolic pathways, growth hormone signaling, and related biological processes. This content is provided solely for scientific and educational purposes and does not constitute medical, treatment, or therapeutic guidance.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety.

Educational guide for reconstitution and daily research

Standard FDA-Approved Protocol (3.0 mL = ~3.33 mg/mL)

Week	Daily Blend (mcg)	Volume (mL)
Week 1	1 mg / 1000 mcg	30 units (0.30 mL)
Weeks 2–12+	2 mg / 2000 mcg	60 units (0.60 mL)

Frequency: Research methodologies and study parameters vary depending on the objectives, laboratory conditions, and experimental design. Scientific investigations continue to evaluate Tesamorelin’s biological properties and mechanisms of action under controlled research settings. This information is provided solely for scientific and educational purposes and does not include administration or treatment recommendations.

Reconstitution Steps

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Research timelines and study methodologies vary depending on the objectives, laboratory conditions, and experimental design. This content is provided for scientific and educational purposes only and does not include schedules or treatment protocols.

Concise summary of the FDA-approved once-daily regimen.

Goal: Reduce visceral adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation.
Schedule: Study duration and research timelines may vary depending on the research design.
Research Range: 2 mg (2000 mcg) daily after Week 1 titration.
Reconstitution: 3.0 mL per 5 mg vial (~3.33 mg/mL) for accurate measurement.
Storage: Lyophilized refrigerated; reconstituted refrigerated up to 7 days; avoid freeze-thaw.

FDA-approved daily research approach with tolerability titration.

Week 1: 1 mg (1000 mcg) once daily to assess tolerability.
Week 2: 2 mg (2000 mcg) once daily (standard FDA-approved research).
Frequency: Once per day (subcutaneous), preferably in the evening.
Cycle Length: 12–26 weeks; clinical trials support up to 52 weeks with monitoring.
Timing: Timing and study conditions may vary depending on the research protocol.

Proper storage preserves peptide quality and efficacy.

Lyophilized: Store at 2–8 °C (35.6–46.4 °F); newer formulations (Egrifta SV) stable at 20–25 °C (68–77 °F) before reconstitution.
Reconstituted (with bacteriostatic water): Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days.
Reconstituted (with sterile water): Use immediately; discard any unused portion.
Do not freeze reconstituted solution; avoid repeated freeze-thaw cycles.

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container
Research procedures may vary depending on the study design and laboratory protocols.
Inject slowly; wait a few seconds before withdrawing the needle.
Monitor IGF-1 levels periodically due to potent GH stimulation; observe blood glucose in diabetic patients.
Document daily research and site rotation to maintain consistency.

Tesamorelin mimics natural human GHRH by binding to pituitary GHRH receptors, triggering pulsatile growth hormone secretion and consequent IGF-1 elevation. This cascade promotes lipolysis (fat breakdown), protein synthesis, and favorable metabolic shifts. In HIV-associated lipodystrophy, daily tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles over 6–12 months. Research also explores tesamorelin’s potential to reduce liver fat in NAFLD patients and enhance cognitive function in older adults by restoring age-related GH/IGF-1 declines.

Observations from clinical trials and FDA-approved use.

Potential Benefits:

Significant reduction in visceral adipose tissue (measurable after 3–6 months).
Improved lipid profiles and potential liver fat reduction in NAFLD.
Enhanced cognitive function in older adults (research ongoing).
Well-tolerated with maintained benefits during continuous use up to 52 weeks.

Common Side Effects:

Research Observations: Research findings and laboratory observations may vary depending on the study design, methodology, and experimental conditions.
Musculoskeletal symptoms: Joint pain (arthralgia), muscle aches, peripheral edema (mild swelling).
Carpal tunnel symptoms: Occasional tingling or numbness in extremities (research -dependent, reversible).
Metabolic monitoring: IGF-1 elevation requires monitoring; small increases in HbA1c observed in some patients.

Contraindications:

Complementary strategies for optimal outcomes.

Combine with a balanced, protein-forward diet to support GH/IGF-1 anabolic effects.
Integrate resistance training and aerobic activity to maximize fat loss and metabolic benefits.
Prioritize 7–9 hours of quality sleep to optimize natural GH pulsatility.
Manage stress through mindfulness or relaxation techniques to support adherence and recovery.

General subcutaneous guidance from clinical best‑practice resources.

Clean the vial stopper and skin with alcohol swabs; allow to air-dry completely.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue
Insert the needle at 90° (if adequate subcutaneous fat) or 45° (if lean)
Release the pinch, then inject slowly; wait 2–3 seconds before withdrawing.
Rotate sites systematically (abdomen avoiding 2‑inch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy.
Dispose of used syringes immediately in a puncture-proof sharps container.

We recommend Vitality Labs Peptides for high-purity Tesamorelin (5 mg).

Why Vitality Labs Peptides?

This content is for educational purposes only and is not medical advice.

Explore related research protocols and background reading for BPC-157 + TB-500.

Tesamorelin – LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

— National Institutes of Health, NIDDK (2018)

Tesamorelin (Subcutaneous route) – Drug Information

— Mayo Clinic / IBM Merative (2025)

Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials

— J. Clin. Endocrinol. Metab. (2010)

Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: A randomized, placebo-controlled trial

— PLoS ONE (2017)

Tesamorelin can improve cognitive function (Research Highlight)

— Nature Reviews Endocrinology (2012)

Tesamorelin Research Information– MedlinePlus Drug Information

— MedlinePlus (U.S. National Library of Medicine) (2025)

EGRIFTA SV (tesamorelin) – Full Prescribing Information

— Theratechnologies, Inc. (FDA Label) (2024)

Tesamorelin: Uses, Side Effects, Warnings

— Drugs.com (AHFS Monograph & Patient Info) (2025)

Tesamorelin – LiverTox (Safety Profile)

— NIH NIDDK LiverTox Database (2018)

Administration of Parenteral Medications – Nursing Skills (Open RN Textbook)

— Open RN, Chippewa Valley Technical College (2023)

Vitality Labs -Tesamorelin 5 mg

— Quality and batch documentation for research-grade tesamorelin